08/21/2026
GLPs and breast cancer recurrence: the science is more interesting than you think.
For years, we’ve known that obesity, insulin resistance, hyperinsulinemia, and chronic inflammation are associated with poorer breast cancer outcomes.
Now, researchers are asking a compelling question: Could improving metabolic health influence recurrence risk?
Early observational research suggests an association between GLP use and improved outcomes in breast cancer survivors, including lower recurrence and mortality. But it’s important to be precise: these studies do not prove that GLP medications prevent cancer recurrence. Randomized clinical trials are still needed.
What makes the research particularly interesting is the biology. GLP medications can influence several interconnected systems:
◼️ Body composition: reducing excess adipose tissue, which is hormonally active
◼️ Insulin sensitivity: improving metabolic function and potentially reducing chronic hyperinsulinemia
◼️ Inflammation: addressing inflammatory signaling associated with metabolic dysfunction
◼️ Cellular biology: emerging research is exploring effects on metabolism, oxidative stress, immune signaling, and growth pathways
The takeaway isn’t that GLPs are a cancer treatment. It’s that metabolic health may be an underappreciated part of the cancer conversation.
At Raden Wellness, we believe the most meaningful questions often exist between specialties. Hormones, metabolism, inflammation, nutrition, cellular function, and longevity don’t operate independently.
The body is a system. So should be the way we care for it.
This content is for educational purposes only and does not constitute medical advice. GLP-1 therapy should be individualized and discussed with your physician, particularly if you have a history of cancer.
WomensHealth Oncology LongevityMedicine IntegrativeMedicine Healthspan
